Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) ...
Czech researchers have discovered that nanoplastics can weaken the lungs’ natural defence system, raising fresh concerns ...
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, sponsored an oral presentation at the ATS 2026 International Conference that is taking place ...
ORJ-001 achieved therapeutic exposure and was well tolerated in Phase 1 study, supporting company’s plans to initiate Phase 2 clinical trial in IPF patients ...
Savara is transitioning from a single-asset biotech to a rare disease commercial infrastructure. Click here to read more on ...
Microplastics (MP) are the subject of intensive medical research, but little is yet known about their effects on the immune ...
Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.
For the first time, scientists have directly measured how smoking changes the mechanical behavior of human lung tissue.
Our lungs have evolved to heal from damage, but some smokers will suffer irreversible effects It used to be thought that the lungs couldn’t regenerate,” says Dr Charlotte Dean, head of the lung ...
As cases mount, industry pushback is delaying federal rules that would reduce miners’ exposure to deadly silica dust.
The gut microbiota has emerged as a critical determinant of systemic immune homeostasis, inflammation, and metabolic regulation, with growing relevance in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results